PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B
暂无分享,去创建一个
[1] A. Boonstra,et al. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection , 2020, Frontiers in Immunology.
[2] S. Milstein,et al. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice. , 2020, Gastroenterology.
[3] Anh-Hoa Nguyen,et al. Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study. , 2019, Journal of hepatology.
[4] M. Raftery,et al. The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance , 2019, Front. Cell. Infect. Microbiol..
[5] U. Protzer,et al. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. , 2019, Gastroenterology.
[6] R. Ferris,et al. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions , 2018, Journal of Virology.
[7] S. Dowdy,et al. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. , 2018, Nucleic acid therapeutics.
[8] L. Cova. Present and future DNA vaccines for chronic hepatitis B treatment , 2017, Expert opinion on biological therapy.
[9] E. Gane. Future anti‐HBV strategies , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[10] A. Bertoletti,et al. Adaptive immunity in HBV infection. , 2016, Journal of hepatology.
[11] J. Larkin,et al. Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.
[12] D. Busch,et al. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. , 2016, Vaccine.
[13] Jia Liu,et al. Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck , 2014, Medical Microbiology and Immunology.
[14] Jia Liu,et al. Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection , 2014, PLoS pathogens.
[15] M. Bourgine,et al. Adeno-Associated Virus-Mediated Gene Transfer Leads to Persistent Hepatitis B Virus Replication in Mice Expressing HLA-A2 and HLA-DR1 Molecules , 2013, Journal of Virology.
[16] T. Novobrantseva,et al. Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8+ T Cell-mediated Hepatic Antiviral Immunity , 2013, Molecular therapy. Nucleic acids.
[17] Wenhui Li,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.
[18] Percy A. Knolle,et al. Living in the liver: hepatic infections , 2012, Nature Reviews Immunology.
[19] Chien-Jen Chen,et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. , 2010, Gastroenterology.
[20] G. Lau,et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. , 2007, Vaccine.
[21] G. Freeman,et al. PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1 , 2007, The Journal of Immunology.
[22] C Upton,et al. Encoding of a homolog of the IFN-gamma receptor by myxoma virus. , 1992, Science.